Clinical significance of a serum CA 15-3 surge and the usefulness of CA 15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 124, Issue 3, 2010, Pages 879-882

  Wu, Shih Chung ^a   Chou, Fong Fu ^a   Rau, Kun Ming ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; METASTASIS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; TREATMENT RESPONSE; TUMOR CELL DESTRUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG MONITORING; FEMALE; HUMANS; KINETICS; MUCIN-1; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME; UP-REGULATION;

EID: 78649244090     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1117-3     Document Type: Letter

References (24)

1. HS Kim YH Park MJ Park, et al. 2009 Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer Breast Cancer Res Treat 118 89 97 1:CAS:528:DC%2BD1MXht1GmtbfO 10.1007/s10549-009-0377-2 19322651
2. R Molina G Zanon X Filella, et al. 1995 Use of serial carcinoembryonic antigen and CA15.3 assays in detecting relapses in breast cancer patients Breast Cancer Res Treat 36 41 48 1:STN:280:DyaK28%2FnsFyitg%3D%3D 10.1007/BF00690183 7579505
3. MF Hou YL Chen TF Tseng, et al. 1999 Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer Kaohsiung J Med Sci 15 520 528 1:CAS:528:DyaK1MXnsFSgu74%3D 10561976
4. D Kufe G Inghirami M Abe, et al. 1984 Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors Hybridoma 3 223 232 1:STN:280:DyaL2M%2FltlWmuw%3D%3D 10.1089/hyb.1984.3.223 6094338
5. GG Klee WE Schreiber 2004 MUC1 gene-derived glycoprotein assays for monitoring breast cancer (CA15-3, CA27.29, BR) Arch Pathol Lab Med 128 1131 1135 1:CAS:528:DC%2BD2cXptVOms74%3D 15387710
6. MA Reddish N Helbrecht AF Almeida, et al. 1992 Epitope mapping of MAb B27.29 within the peptide core of the malignant breast carcinoma-associated mucin antigen coded for by the human MUC1 gene J Tumor Marker Oncol 7 19 27
7. MM Gourevitch S Von Mensdorff-Pouilly SV Litvinov, et al. 1995 Polymorphic epithelial mucin (MUC-1)-containing circulating immunocomplexes in carcinoma patients Br J Cancer 72 934 938 1:CAS:528:DyaK2MXptlKjtbg%3D 7547243
8. HS Kim YH Park MJ Park, et al. 2009 Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer Breast Cancer Res Treat 118 89 97 1:CAS:528:DC%2BD1MXht1GmtbfO 10.1007/s10549-009-0377-2 19322651
9. MJ Duffy 2006 Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52 345 351 1:CAS:528:DC%2BD28Xit1ShtrY%3D 10.1373/clinchem. 2005.059832 16410341
10. Hashimoto K, Yonemori K, Katsumata N, et al (2010) Prediction of progressive disease using tumor markers in metastatic breast cancer patients without target lesions in first-line chemotherapy. Ann Oncol [Epub ahead of print]
11. D Baskić P Ristić S Matić, et al. 2007 Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer Biomarkers 12 657 667 10.1080/13547500701520563 17852076 (Pubitemid 350048080)
12. M Tampellini A Berruti R Bitossi, et al. 2006 Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients Breast Cancer Res Treat 98 241 248 1:CAS:528:DC%2BD28XnvVGlsr4%3D 10.1007/s10549-005-9155-y 16670941 (Pubitemid 44195593)
13. MJ Duffy 2001 Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 34 347 352 1:CAS:528:DC%2BD3MXnsFSrs7w%3D 10.1016/S0009-9120(00)00201-0 11522269 (Pubitemid 32777841)
14. AS Mall 2008 Analysis of mucins: role in laboratory diagnosis J Clin Pathol 61 1018 1024 1:STN:280:DC%2BD1crkvFGqtA%3D%3D 10.1136/jcp.2008.058057 18641408
15. N Jonckheere I Van Seuningen 2010 The membrane-bound mucins: From cell signaling to transcriptional regulation and expression in epithelial cancers Biochimie 92 1 11 1:CAS:528:DC%2BD1MXhsFyms73L 10.1016/j.biochi.2009.09.018 19818375
16. S Yonezawa M Goto N Yamada, et al. 2008 Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior Proteomics 8 3329 3341 1:CAS:528:DC%2BD1cXhtVGqs7zO 10.1002/pmic.200800040 18651706
17. S Bafna S Kaur SK Batra 2010 Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells Oncogene 29 2893 2904 1:CAS:528:DC%2BC3cXjvFarsbY%3D 10.1038/onc.2010.87 20348949
18. NJ Vogelzang PH Lange A Goldman, et al. 1982 Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors Cancer Res 42 4855 4861 1:STN:280:DyaL3s%2FisVyjsQ%3D%3D 6181870
19. A Horwich MJ Peckham 1986 Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis Cancer Treat Res 70 1329 1331 1:STN:280:DyaL2s%2FivVSnsg%3D%3D
20. A Sella CN Sternberg I Skoneczna, et al. 2008 Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer BJU Int 102 1607 1609 1:CAS:528: DC%2BD1MXhtVWktb4%3D 10.1111/j.1464-410X.2008.07873.x 18990177
21. T Nelius S Filleur 2009 PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy Prostate 69 1802 1807 1:STN:280:DC%2BD1MjhvVKisg%3D%3D 10.1002/pros.21024 19676083
22. R De Wit L Collette R Sylvester 1998 Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance Br J Cancer 78 1350 1355 9823978
23. X An PR Ding XJ Xiang, et al. 2010 Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy Biomarkers 15 243 248 1:CAS:528:DC%2BC3cXltVyhtbo%3D 10.3109/13547500903477377 20121626
24. S Ailawadhi A Sunga A Raiput, et al. 2005 Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer Oncology 70 49 53 10.1159/000091184